Skip to main content

Treatment Clinical Trials for Advanced Carcinoma Of Unknown Primary

Review the advanced carcinoma of unknown primary treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-13 of 13

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer after Previous Treatment
Status: Active
Location: 171 locations
Evaluating Residual Circulating Tumor DNA Levels After Surgery for Directing Adjuvant Treatment in Patients with HPV-Mediated Oropharynx Cancer, SAVAL Trial
Status: Active
Location: 5 locations
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Status: Active
Location: 5 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Risk-Directed Postoperative Radiation Therapy and Cisplatin for the Treatment of Stage I-II HPV-Related Oropharynx Squamous Cell Carcinoma, The Minimalist Trial-2 (MINT-2)
Status: Active
Location: 2 locations
Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Status: Active
Location: 2 locations
Atezolizumab and Tiragolumab for the Treatment of Patients with Refractory Locally Advanced, Metastatic or Recurrent Cancer of Unknown Primary
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cetuximab and Cemiplimab before Surgery for the Treatment of Resectable Head and Neck Squamous Cell Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Personalized Treatment with Surgery, Radiation and/or Chemotherapy for Patients with Stage I-II HPV-related Squamous Cell Carcinoma of the Oropharynx
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Decitabine in Combination with Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Zanzalintinib with Pembrolizumab and Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas